Ultra-High Titer of 5E8 TU/mL: Yeasen UltraLV Transfection Reagent Empowers In Vivo CAR-T Industrialization

In vivo CAR-T is a popular and innovative direction in the field of cell and gene therapy (CGT). Featuring core advantages such as eliminating the need for ex vivo sorting and culture, enabling in-situ T-cell modification, and streamlining operations, it revolutionizes the traditional CAR-T treatment paradigm and provides a brand-new solution for the treatment of refractory diseases.

Currently, in vivo CAR-T is mainly divided into two technological routes: lentiviral vector delivery and LNP delivery. Among them, lentiviral vectors have become one of the mainstream solutions for industrialization due to their stable expression, mature safety profile, and broad adaptability.

 Figure CAR-T Construction Workflows

However, the large-scale production of lentiviral vectors (LVV) remains a core bottleneck restricting the industrialization of in vivo CAR-T. To address industry technical pain points, Yeasen Biotechnology—relying on its AI-driven molecular design and R&D platform, deeply cultivating PEI compound modification and engineering technology, and establishing an intelligent R&D closed-loop and compound resource library—has grandly launched the UltraLV Lentivirus Packaging Specialized Transfection Reagent, meeting the needs of large-scale production in both suspension and adherent systems. Featuring original hydrogen bond-hydrophobic dual-modification technology, the product integrates five core advantages: ultra-high titer, low cytotoxicity and high stability, extremely simple operation, comprehensive compliance, and controllability. It precisely solves the mass-production bottleneck of lentivirus and fully empowers the industrialization of in vivo CAR-T and various lentiviral gene therapy projects.

AI-Intelligent R&D Empowerment Establishes a Solid Product Technology Foundation

Different from traditional industry trial-and-error R&D, Yeasen UltraLV transfection reagent was born out of an intelligent R&D system combining AI and high-throughput validation, thoroughly realizing a paradigm shift from "experience-driven" to "data-intelligence-driven". Relying on deep-learning molecular simulation technology, it can rapidly screen multiple PEI molecular modification schemes, accurately lock onto high-potential lead compounds, compress a traditional multi-year R&D cycle into just a few months, and drastically reduce R&D trial-and-error costs.

At the same time, paired with an automated high-throughput experimental platform, it performs multi-dimensional performance validation on candidate compounds, continuously iterating and optimizing combined with data-driven models to precisely solve the pain points of strong cytotoxicity and insufficient transfection stability inherent in traditional PEI reagents. Through a unique hydrogen bond-hydrophobic dual-modification process, it not only enhances the stability of transfection complexes and improves cell membrane fusion efficiency, but also effectively neutralizes the excessive positive charge of PEI, reducing non-specific damage to cells. This achieves a triple innovation in transfection efficiency, biocompatibility, and product stability, providing core technical support for ultimate product performance.

• Enhanced Stability:

The modified groups introduce hydrogen-bonding interactions between the transfection reagent and nucleic acids, effectively complementing electrostatic adsorption and improving the stability of transfection complexes.

• Improved Transfection Efficiency:

The modified groups possess certain hydrophobic properties, which significantly enhance adhesion and endocytosis efficiency, promoting the fusion of transfection complexes with the cell membrane.

• Reduced Cytotoxicity:

The hydrophobic modification neutralizes the excessively strong positive charges of PEI, mitigating non-specific damage to the cell membrane and reducing cytotoxicity.

Ultimate Product Performance: High Titer of 5E8 TU/mL Cuts Costs, Increases Efficiency, and Outpaces Competitors

Performance innovation is the core competitiveness of UltraLV. Relying on underlying technological breakthroughs, this reagent achieves a massive boost in lentivirus yield within 293 suspension systems, with viral supernatant titers reaching up to 5E8 TU/mL—surpassing mainstream similar products by 2-3 times and breaking the monopoly of imported performance. It features low cytotoxicity and is friendly to downstream processes. High titers can reduce feeding volumes, culture volumes, and purification losses in large-scale production, lowering comprehensive costs such as consumables, labor, and energy consumption, and adapting to large-scale production in industrial-grade bioreactors.

The operational workflow has achieved an ultra-simple upgrade, supporting a one-step serum-free protocol. Plasmids and transfection reagents can be directly added to serum-free medium to prepare complexes, simplifying procedures, shortening working hours, and reducing human operation errors to meet the standardized and automated production requirements of large-scale manufacturing.

The product demonstrates significant advantages in safety and stability: gentle molecular modifications reduce cytotoxicity, yielding cell viability of up to 95% at 48 hours post-transfection, reducing host cell residuals and enhancing viral vector purity and clinical safety. The product can withstand 10 freeze-thaw cycles, remains stable at 37°C for two weeks, and exhibits excellent batch-to-batch consistency, solving performance fluctuations during storage, transportation, and production of conventional reagents, thus adapting to complex industrial production scenarios.

Comprehensive Compliance System: Support for Clinical and Commercialization

For the industrialization of CGT drugs, compliance is the core bottom line. Yeasen Biotechnology has built a full-chain compliance system spanning raw materials, production, quality control, and filing. The UltraLV GMP-grade transfection reagent fully meets China-US IND filing standards, providing robust escort for clinical projects. The company owns a standardized GMP production base, produces in compliance with cGMP and ISO13485 medical device quality management system standards, adopts modular cleanroom design to support flexible capacity expansion and custom manufacturing, and can fully satisfy global commercial supply demands.

A complete set of compliance documents is available, backed by independent patents. Furthermore, PEI residual detection methods can be provided free of charge to partner clients. It can smoothly pass international official audits and clinical inspections, completely resolving compliance concerns for pharmaceutical companies during project filings.

Abundant Practical Implementation Experience: Empowering Projects from IND to Clinical Stage

Backed by excellent product performance and a comprehensive compliance system, Yeasen transfection reagents have accumulated a massive volume of real-world industrialization implementation cases. They have successfully empowered multiple projects to smoothly advance into IND filing and clinical stages, with product performance and compliance documentation recognized by regulatory authorities, demonstrating rich practical experience.

Compared to ordinary research-grade reagents, Yeasen's GMP-grade products can seamlessly integrate into the entire drug development workflow—providing full-cycle technical and compliance support from early process development, small-scale and pilot trials, to commercial mass production and clinical filings. This effectively averts R&D risks such as process fluctuations and lack of compliance, helping enterprises substantially shorten R&D cycles, raise filing pass rates, and accelerate the commercial landing of innovative gene therapy drugs.

Deep Cultivation in Upstream Core Tracks: Empowering Industrial Upgrading

Yeasen Biotechnology has deeply cultivated the upstream core raw materials field of life sciences for many years, building seven core technology platforms with comprehensive R&D, production, and quality inspection systems, serving over 20,000 clients globally. Relying on continuous technological iteration capabilities and scale production advantages, the company achieves full-category coverage of transfection reagent products, adapting to diverse scenario demands including basic research, protein expression, virus packaging, and CGT drug development.

Moving forward, Yeasen Biotechnology will continue to rely on its AI-intelligent R&D platform to continually iterate the performance of the UltraLV series, optimize lentiviral industrial production processes, and empower in vivo CAR-T and various gene therapy innovative treatments with higher-performance, more compliant, and more cost-effective, contributing to the high-quality, autonomous, and internationalized development of CGT industry.

Product Ordering Information